CAEL-101 not checked
Alexion Pharmaceuticals, Inc. · Ch mAb 11-1F4
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.”In the company’s words, NCT04512235 on ClinicalTrials.gov
- Tested for
- AL Amyloidosis (2 trials)
- Main trialPhase 3
- “AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves overall survival, reduces cardiovascular related hospitalizations and it is safe and well tolerated…”In the company’s words, NCT04512235 on ClinicalTrials.gov
- Other names
- Anselamimab · Ch mAb 11-1F4
Other drugs for AL Amyloidosis
- EtentamigAbbVie · Phase 3
- LinvoseltamabRegeneron · Phase 3
- NXC-201Nexcella Inc. · Phase 1/2
- Equecabtagene AutoleucelNanjing IASO Biotechnology Co., Ltd. · Phase 2
- FKC289Shenzhen Fosun Kairos Biotechnology Co., Ltd. · Phase 1/2
- AZD0120AstraZeneca · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 8 Apr 2025 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) | |
| Phase 3Active, not recruiting | 10 May 2025 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) | |
| Phase 2Completed | 14 Nov 2023 | A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis | |
| Phase 1Completed | 13 Jul 2017 | Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026